乙型肝炎病毒基因型对干扰素α2b应答的影响  

Effect of hepatitis B virus genotypes on response to interferon α2b in the treatment of chronic hepatitis B

作　　者：肖扬[1] 胡操寒[1] 周岳进[1] 谢庆荣[1] 朱冰星[1] 胡侠[1] 王开鉴[1] 张文静[1] 

机构地区：[1]中国人民解放军第118医院肝病科,浙江温州325000

出　　处：《临床肝胆病杂志》2006年第2期105-106,共2页Journal of Clinical Hepatology

摘　　要：在HBV基因型特异引物下聚合酶链反应(PCR)扩增并检测1020例慢性乙型肝炎患者血清HBVDNA。其中136例接受干扰素α2b治疗,疗程6个月;观察患者乙型肝炎病毒血清标志物、HBVDNA、丙氨酸转氨酶(ALT)。1020例乙型肝炎患者中966例有基因分型结果;136例接受干扰素α2b治疗综合疗效(HBeAg阴转、HB-VDNA阴转、ALT复常)B型患者为40.9%(18/44),优于C型25.8%(16/62)及B/C混合型16.7%(5/30)(P>0.05)。乙型肝炎病毒不同基因型可以对干扰素α2b应答产生影响。Amplifing the HBVDNA of 1020 patients with chronic hepatitis B （CHB） under the HBV genotype - specific primers by polymerase chain reaction（ PCR）, its amplified products was detected by Caliper - 1000 microcurrent chip. Among them 136 patients were received interferon α2b for 6 months. All subjects were assessed for loss of HBeAg, presence of anti- HBe, suppression of HBVDNA, and normalization of serum alanine transaminase （ALT）. Among the 1020 patients. 966 cases for HBV genotyping have been determined. At the end of treatment among 136 patients with CHB, the combined response （ HBeAg loss, HBVDNA suppression and ALT normalization） to interferon α2b in the treatment of patients with HBV genotype B was superior in efficacy to patients with HBV genotype C and B/C （40. 9% vs 25.8% and 16. 7% ;P 〉0. 05 ）. The difference of HBV genotypes may have effect on response to interferon α2b in the treatment of CHB.

关 键 词：乙型肝炎病毒 基因型 干扰素Α2B 乙型肝炎E抗原 

分 类 号：R512.62[医药卫生—内科学]